[Clinical experiences with the silver chelate of phosphoric acid-mono-(2-aminoethyl ester) (dermazellon) in dermatology].
D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D004926:Escherichia coli / Q000187:drug effects; D005782:Gels; D006801:Humans; D007709:Klebsiella / Q000187:drug effects; D007871:Leg Ulcer / Q000188:drug therapy; D010755:Organophosphates / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D011511:Proteus / Q000187:drug effects; D011549:Pseudomonas / Q000187:drug effects; D012834:Silver / Q000627:therapeutic use*; D012874:Skin Diseases, Infectious / Q000188:drug therapy* / Q000382:microbiology; D013210:Staphylococcus / Q000187:drug effects
D000891:Anti-Infective Agents, Local; D005782:Gels; D010755:Organophosphates; D009943:Organophosphorus Compounds; D012834:Silver
Klinische Erfahrungen mit dem Silberchelat des Phosphorsäure-mono-(2-aminoäthylesters) (Dermazellon) in der Dermatologie.